FGFR4 has been widely studied in other malignancies, such as breast, prostate, colorectal, gastric, and head and neck cancers, where its overexpression and polymorphic variants, particularly rs351855, have been linked to tumor progression, therapy resistance, and poor prognosis [14,15]. This evidence concerns the gene FGFR4 and head and neck cancer.